In the last years, the application of "nanotechnology “to the field of “medicine” surely represented the most innovative strategy to cop_20e with diseases and it could be named as nanomedicine applied to difficult-to-treat diseases. As known, in this field of research, the most important goal to be reached is an increase in selectivity and specificity of drug action. Several results with stimulating findings in preclinical or clinical phases have been reached by using nanocarriers, delivering agents to targeted pathologies, and among them, it is known that neuro-pathologies represent a stimulating issue. In fact, the pharmaceutical treatment of Central Nervous System (CNS) disorders is the second largest area of therapy, following cardiovascular diseases. Nowadays, non-invasive drug delivery systems for CNS are actively studied. In fact, the development of new delivery systems (nanoparticles and liposomes) started with the discovery that properly surface-engineered colloidal vectors, with a diameter around 200 nm, were shown to be able to cross the Blood-Brain Barrier without apparent damage, and to deliver drugs or genetic materials into the brain. During this talk, an overview will be presented considering the most recent literature results of nanomedicine applied to brain diseases, carried out with all the most popular kinds of nanoparticulate systems, focusing in particular on immune-nanoparticles and peptide-decorated nanosystems able to target the CNS, with in vivo and in vitro evidences investigating the pathway for BBB crossing and CNS localization of engineered nanoparticles. The brain localization and the multi-modal pathways for BBB crossing highlighted the endocytosis as preferential pathway; moveover, in vitro test on hippocampal neurons showed the presence of cell-to-cell transport of nanoparticles.

Nanoparticles and the BBB crossing: in vivo and in vitro upcomings / Tosi, Giovanni; Bondioli, Lucia; Ruozi, Barbara; Andreas, Grabrucker; Vilella, Antonietta; Zoli, Michele; Rivasi, Francesco; Vandelli, Maria Angela; Forni, Flavio. - In: AMINO ACIDS. - ISSN 1438-2199. - STAMPA. - 1:(2011), pp. 1-1. ((Intervento presentato al convegno 12 congress on Amino Acids, peptides and proteins tenutosi a Benjiing China nel 1-5- August 2011.

Nanoparticles and the BBB crossing: in vivo and in vitro upcomings

TOSI, Giovanni;BONDIOLI, Lucia;RUOZI, Barbara;VILELLA, ANTONIETTA;ZOLI, Michele;RIVASI, Francesco;VANDELLI, Maria Angela;FORNI, Flavio
2011

Abstract

In the last years, the application of "nanotechnology “to the field of “medicine” surely represented the most innovative strategy to cop_20e with diseases and it could be named as nanomedicine applied to difficult-to-treat diseases. As known, in this field of research, the most important goal to be reached is an increase in selectivity and specificity of drug action. Several results with stimulating findings in preclinical or clinical phases have been reached by using nanocarriers, delivering agents to targeted pathologies, and among them, it is known that neuro-pathologies represent a stimulating issue. In fact, the pharmaceutical treatment of Central Nervous System (CNS) disorders is the second largest area of therapy, following cardiovascular diseases. Nowadays, non-invasive drug delivery systems for CNS are actively studied. In fact, the development of new delivery systems (nanoparticles and liposomes) started with the discovery that properly surface-engineered colloidal vectors, with a diameter around 200 nm, were shown to be able to cross the Blood-Brain Barrier without apparent damage, and to deliver drugs or genetic materials into the brain. During this talk, an overview will be presented considering the most recent literature results of nanomedicine applied to brain diseases, carried out with all the most popular kinds of nanoparticulate systems, focusing in particular on immune-nanoparticles and peptide-decorated nanosystems able to target the CNS, with in vivo and in vitro evidences investigating the pathway for BBB crossing and CNS localization of engineered nanoparticles. The brain localization and the multi-modal pathways for BBB crossing highlighted the endocytosis as preferential pathway; moveover, in vitro test on hippocampal neurons showed the presence of cell-to-cell transport of nanoparticles.
12 congress on Amino Acids, peptides and proteins
Benjiing China
1-5- August 2011
1
1
1
Tosi, Giovanni; Bondioli, Lucia; Ruozi, Barbara; Andreas, Grabrucker; Vilella, Antonietta; Zoli, Michele; Rivasi, Francesco; Vandelli, Maria Angela; Forni, Flavio
Nanoparticles and the BBB crossing: in vivo and in vitro upcomings / Tosi, Giovanni; Bondioli, Lucia; Ruozi, Barbara; Andreas, Grabrucker; Vilella, Antonietta; Zoli, Michele; Rivasi, Francesco; Vandelli, Maria Angela; Forni, Flavio. - In: AMINO ACIDS. - ISSN 1438-2199. - STAMPA. - 1:(2011), pp. 1-1. ((Intervento presentato al convegno 12 congress on Amino Acids, peptides and proteins tenutosi a Benjiing China nel 1-5- August 2011.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/657835
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact